VEGF/mTOR combination for non-clear cell kidney cancer

The combination of vascular endothelial growth factor (VEGF)-directed and mammalian target of rapamycin (mTOR)-directed therapies has not been very successful for the treatment of renal cell carcinoma (RCC). However, a recent study published in the Journal of Clinical Oncology has shown some success in non-clear cell RCC. Researchers combined the VEGF-directed drug, bevacizumab, with the […]

read more

Nivolumab associated with improved quality of life versus everolimus

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week, indicated that nivolumab was associated with improvement in health-related quality of life (HRQoL) compared with everolimus in previously treated patients with advanced renal cell carcinoma (RCC). In the phase 3 CheckMate 025 study, previously treated patients with advanced renal […]

read more

Lenvatinib plus everolimus improves progression-free survival in renal cell carcinoma

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week show that lenvatinib (Lenvima) plus everolimus (Afinitor) in kidney cancer significantly improved progression free survival (PFS) compared with everolimus or lenvatinib alone. Patients with metastatic renal cell carcinoma (mRCC) treated with lenvatinib plus everolimus following one prior VEGF targeted therapy […]

read more

Cabozantinib extends survival in advanced kidney cancer compared to axitinib

Results from the phase III METEOR clinical trial, which compares cabozantinib (Cabometxy) with everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC) who have had prior anti-angiogenic therapy, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week. The results showed almost a 30% increase in overall survival (OS) compared […]

read more

FDA approves lenvatinib/everolimus combination for kidney cancer

The FDA has approved the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior antiangiogeneic therapy, based on survival and response data from a phase II study. In the trial, known as Study 205, the combination of lenvatinib and everolimus reduced the risk of […]

read more

Sunitinib vs everolimus for advanced non-clear cell kidney cancer

In a recent study published in the journal Lancet Oncology, researchers compared everolimus versus sunitinib in 108 patients with metastatic papillary, chromophobe, or unclassified non–clear-cell renal cell carcinoma (RCC) in a phase 2 randomised, industry-sponsored clinical trial. Nearly two thirds of the patients had papillary histology. Progression-free survival was longer with sunitinib in patients with […]

read more
Showing 41 to 46 of 46 results
  TOP